China Resources Pharmaceutical Group Ltd (3320.HK) stock: key figures, P/E, revenue and dividend
Health Care · Hong Kong · ISIN HK0000311099
China Resources Pharmaceutical Group Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 257.67 bn CNY | 269.57 bn CNY |
| Gross profit | 40.69 bn CNY | 57.68 bn CNY |
| EBIT | 11.81 bn CNY | 16.19 bn CNY |
| Net income | 3.35 bn CNY | 4.05 bn CNY |
| Diluted EPS – continuing operations | 0.53 CNY | 0.83 CNY |
Full history since 2013, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About China Resources Pharmaceutical Group Ltd
China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular, metabolism, intravenous infusion, and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operating retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, Kun Zhong Yao, and Tasly to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited operates as a subsidiary of CRH (Pharmaceutical) Limited.
More stocks
- Organon & Co. (OGN)
- Ta Chen Stainless Pipe Co Ltd (2027.TW)
- Vidrala SA (VID.MC)
- Manchester United Ltd (MANU)
- Beijing Tiantan Biological Products Corp Ltd (600161.SS)
- Zhengzhou Coal Mining Machinery Group Co Ltd (601717.SS)
- CareDx, Inc. (CDNA)
- LXP Industrial Trust (LXP)
- Fastly, Inc. (FSLY)
- AVIS BUDGET GROUP, INC. (CAR)
- SMG Swiss Marketplace Group Holding AG (SMG.SW)
- Andon Health Co Ltd (002432.SZ)
Not investment advice. All data without warranty, price as of 23.10.2026. Details in the risk notice.